Polycystic kidney disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PKD1 1
• SGLT2 1
• CFTR 1
• AMPK 1
• STAT3 0
• GLP-1 1
• mTOR 0
• MUC1 0
• CDK4/6 0
• DMD 1
• EGFR 0
• G6PD 0
• HER2 0
• HTT 1
• IL-6 0
• MAPK 0
• NF1 1
• NRF2 1
• PD-L1 0
• PKM2 0
• PPAR 0
• SMN1 1
• STING 0
• TLR4 0
• TNF 0
• YAP 0

24 of 255 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting Glutamine (Q) Metabolism in the Renal Ciliopathies (QrCiliopathies)

  Ospedale San Raffaele Srl· Milano, Italy· EU contribution €150,000· until Jan 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing genetic medicines for inherited kidney disease (RENALGENE)

  Fundacion Para la Investigacion Medica Aplicada Fima· Pamplona, Spain· EU contribution €1,500,000· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  A Novel Glutamine (Q) Sensory Role for Primary Cilia: Implications for Health and Disease (QtCilia)

  Ospedale San Raffaele Srl· Milano, Italy· EU contribution €2,500,000· until Oct 2029

3 of 3 running projects, newest first. Listed amounts together: €4.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

  NCT07228364· AstraZeneca· Source

• Bempedoic Acid Therapy for Polycystic Kidney Disease

  NCT07282821· Kenneth Hallows· Source

• A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

  NCT06734234· GlaxoSmithKline· Source

• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05510115· University of Colorado, Denver· Source

• Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

  NCT03901521· Weill Medical College of Cornell University· Source

• Canadian Medical Assessment of JINARC™ Outcomes Registry

  NCT02925221· Otsuka Canada Pharmaceutical Inc.· Source

• Daily Caloric Restriction in ADPKD

  NCT04907799· University of Colorado, Denver· Source

• Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

  NCT06582875· University of Colorado, Denver· Source

• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04786574· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

  NCT06036992· University Hospital, Brest· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Organoids 3
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 7
• Gene Expression Profiling 4
• Whole Genome Sequencing 2
• Exome Sequencing 9
• Metabolomics 1
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 2
• Deep Learning 4
• Cohort Studies 13
• Genome-Wide Association Study 2

• A novel inversion at 17q12 disrupting HNF1B gene in a patient with renal cysts and diabetes syndrome.

  BMC Med Genomics, Feb 2026

• Prenatal-Onset Autosomal Dominant Polycystic Kidney Disease: Clinical Spectrum and Genetic Complexity of a Pseudo-Recessive Phenotype.

  Prenat Diagn, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.